Is angiotensin-II an endogenous pro-inflammatory molecule?

Medical Science Monitor

Volumn 11, Issue 5, 2005, Pages

  Das, Undurti N ^a  

^a UND Life Sciences   (United States)

Author keywords

Alzheimer's disease; Angiotensin converting enzyme; Cancer; Free radicals; Insulin resistance; Nitric oxide

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATOPIC DERMATITIS; BIPOLAR DISORDER; BLOOD VESSEL TONE; CANCER; CHRONIC INFLAMMATION; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DEMENTIA; DERMATITIS; ECZEMA; ENZYME ACTIVITY; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PSORIASIS; RECEPTOR BLOCKING; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; STROKE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; FEMALE; FREE RADICALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; NITRIC OXIDE; PREGNANCY; RECEPTORS, ANGIOTENSIN;

EID: 20344397446     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Dezso B et al: Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes. J Hypertension, 1989; 7: 5-11
2. El Bekay R, Alvarez M, Monteserrin A et al: Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB, Blood, 2003; 102: 662-71
3. Hahn AW, Johas U, Buhler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett, 1994; 347: 178-80
4. Girendling KK, Minien CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 1994; 74: 1141-48
5. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med, 1999; 340: 115-26
6. Car H, Harrison DG: Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res, 2000; 87: 840-44
7. Flather MD et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients. Lancet, 2000; 355: 1575-81
8. Pfeffer MA et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003; 349: 1893-906
9. Dickstein K et al: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomized trial. Lancet, 2002; 360: 752-60
10. Blood Pressure Lowering Treatment trialists Collaboration. Lancet, 2003; 362: 1527-35
11. Jong P et al: Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet, 2003; 361: 1843-48
12. Newton R, Kuitert LM, Bergmann M et al: Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem Biophys Res Commun, 1997; 237: 28-32
13. Read MA, Whitley MZ, Williams AJ, Collins T: NF-κB and I κBα: an inducible regulatory system in endothelial activation. J Exp Med, 1994; 179: 503-12
14. Shu HB, Agranoff AB, Nabel EG et al: Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-κB subunits in endothelial and epithelial cells. Mol Cell Biol. 1993; 13: 6283-89
15. Tham DM, Martin-McNulty B, Wang Y-X et al: Angiotensin II is associated with activation of NF-κB-mediated genes and Downregulation of PPARs. Physiol Genomics, 2002; 11: 21-30
16. Brasier AR, Jamaluddin M, Han Y et al: Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor. Mol Cell Biochem, 2000; 212: 155-69
17. Ruiz-Ortega M, Lorenzo B, Ruperez M et al: Systemic infusion of angiotensin II into normal rats activates nuclear factor-κB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol, 2001; 158: 1743-56
18. Dandona P, Kumar V, Aljada A et al: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab, 2003; 88: 4496-501
19. Dohi Y, Ohashi M, Sugivama M et al: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003; 26: 691-97
20. Fliser D, Buchholz K, Haller H: European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflamniation. Circulation, 2004; 110: 1103-7
21. Graninger M, Reiter R, Drucker C et al: Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol, 2004; 44: 335-39
22. Kumar KV, Das UN: Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun, 1993; 19: 59-66
23. Takahashi T, Tanignchi T, Okuda M et al: Participation of reactive oxygen intermediates in the angiotensin II-activated signaling pathways in vascular smooth muscle cells. Ann NY Acad Sci, 2000; 902: 283-87
24. Pueyo ME, Gonzalez W, Nicoletti A et al: Angiotensin II stimulates endothelial cell adhesion molecule - I via nuclear factor-κ activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol, 2000; 20: 645-51
25. Ushio-Fukai M, Alexander RW, Akers M et al: Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999; 274: 22699-704
26. Baeuerle PA, Baltimore D: NF-KB. Ten years after. Cell. 1996; 87: 13-20
27. Baeuerle PA, Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol, 1996; 14: 649-83
28. Ruiz-Ortega M et al: Angiotensin-II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa I activation and monocyte chemoattractant protein-1 synthesis. J Immunol, 1998; 161: 430-39
29. Ruiz-Ortega M et al: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl, 2002; 82: 12-22
30. Ortiz LA et al: Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol, 2002; 282: L1209-L1221
31. Lindmark E, Siegbahu A: Tissue factor regulation and cytokine expression in monocyte-endothelin cell co-cultures: effects of a statin, and ACE-inhibitor and a low-molecular-weight heparin. Thromb. Res, 2002; 108: 77-84
32. Saijinomaa O et al: Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukins-1beta in cultured human entlothelial cells. J. Vasc. Res, 2001; 38: 370-78
33. Wassmann S et al: Interlenkin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circulation Res, 2004; 94: 534-41
34. Hayek T et al: Tissue angiotensin-converting enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis. Arteriosclerosis Thromb. Vasc. Biol, 2003; 23: 2090-96
35. Cipollone F, Fazia M, Iezzi A et al: Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E dependent matrix metalloproteinase activity. Circulation, 2004, 109: 1482-88
36. Quan S, Yang L, Shnouda S et al: Expression of human heme oxygenase-1 in the thick ascending limb attenuates angiotensin II-mediated increase in oxidative injury. Kidney Int, 2004; 65: 1628-39
37. Chen Y, Arrigo AP, Currie RW: Heat shock treatment suppresses angiotensin II-induced activation of NF-kappaB pathway and heart inflammation: a role for IKKB depletion by heat shock? Am J Physiol Heart Circ Physiol, 2004: 287: H1104-H1114
38. Zhao Q, Ishibashi M, Hiasa K et al: Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension, 2004; 44: 26470
39. Kumar KV, Das UN: Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med, 1997: 214: 374-79
40. Das UN: Lipids that matter from infant nutrition to insulin resistance. Prostaglandins Leukot Essen Fatty Acids, 2002; 67: 1-12
41. Das UN, Begin ME, Horrobin DF et al: Clinical significance of essential fatty acids. Nutrition, 1988; 4: 337-41
42. Das UN: Essential fatty acids: Biology and their clinical implication. Asian Pacific J Pharmacol. 1991; 6: 317-30
43. Das UN: Beneficial action (s) of eicosapentaenoic acid/docosahexaenoic acid and nitric oxide in systemic lupus erythematosus. Med. Sci. Res, 1995; 23: 723-26
44. Das UN, Mohan IK, Raju TR: Effect of corticosteroids and eicosapentaenoic acid/docosahexaenoic acid on pro-oxidant and anti-oxidant status and metabolism of essential fatty acids in patients with glomerular disorders. Prostaglandins Leukot Essen Fatty Acids, 2001; 65: 197-203
45. Das UN: Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot. Essen. Fatty Acids, 1995; 52: 387-91
46. Das UN, Vaddadi KS: Essential fatty acids in Huntington's disease. Nutrition, in press, 2004
47. Bunk S: ACEs wild. The Scientist. 2002; 16(24): 22-24
48. Moskowitz DW: Is angiolensin I-converting enzyme a 'master' disease gene? Diabetes Tech. Therapeutics, 2002; 4: 683-711
49. Swan Kumar G, Das UN: Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukotrienes Essential Fatty Acids, 1994; 50: 331-34
50. Sravan Kumar G, Das UN, Vijay Kumar K et al; Effect of n-6 and n-3 fatty acids on the proliferation and secretion of TNF and IL-2 by human lymphocytes in vitro. Nutrition Res, 1992; 12: 815-23
51. Endres S, Ghorbani R, Kelley VE et al: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukins-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 1989; 320: 265-71
52. Kaergel E, Muller DN, Honeck H et al: P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. Hypertension, 2002; 40: 273-79
53. Node K, Huo Y, Ruan X et al: Anti-inflammatory properties of Cytochrome P450 epoxygenase-derived eicosanoids. Science, 1999; 285: 1276-79
54. Jong P, Yusuf S, Rousseau MF et al: Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet, 2003; 361: 1843-48
55. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-towering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003; 362: 1527-35
56. Dirkstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet, 2002; 360: 752-60
57. Flather MD, Yusuf S, Kober L et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet, 2000; 355: 1575-81
58. Pitt B, Poole-Wilson PA, Segal R et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000; 355: 1582-87
59. Pfeffer MA, McMurray JJV, Velazquez EJ et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003; 349: 1893-906
60. Das UN: A radical approach to cancer. Med Sci Monit, 2002; 8(4): RA79-RA92
61. Marx J: Inflammation and cancer. Science, 2004; 306: 966-68
62. Ronquist G et al: Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate, 2004; 58: 50-56
63. Molteni A et al: Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type 1 receptor antagonists. Curr. Pharm. Des, 2003; 9: 751-61
64. Merchan JR et al: In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst. 2003; 95: 388-99
65. Walther T et al: Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J, 2003; 17: 2061-67
66. Fabre JE, Rivard A, Magner M et al: Tissue inhibition of angiotensin converting enzyme activity stimulates angiogenesis in vivo. Circulation, 1999; 99: 3043-49
67. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotel J: Angiotensin II, cell proliferation and angiogenesis regulator: biochemical and therapeutic implications in cancer. Curr Vasc Pharmacol. 2004; 2: 385-99
68. Yasumaru M et al: Inhibition of angiotensin II activity enhanced the antitumor effect of cyclo-oxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res, 2003; 63: 6726-34
69. Heart Outcomes Prevention Evaluation Study Investigators. Effects of An angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342; 145-53
70. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcome in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000; 355: 253-59
71. Fox KM: EURopean trial On reduction of cardiac events with Perindopril in sable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (EUROPA study). Lancet, 2003; 362: 782-88
72. Boos C: Cardiovascular protection with ace inhibitors-more HOPE for EUROPA? Med Sci Monit. 2004; 10(12): SR23-SR28
73. Mancini GB: Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease. Cardiovasc Drugs Ther, 1996; 10: 609-12
74. Suzuki Y, Ruiz-Ortega M, Lorenzo O et al: Inflammation and angiotensin II. Int J Biochem Cell Biol, 2003; 35: 881-900
75. Nishimoto M, Takai S, Fukumoto H et al: Increased local angiotensin II formation in aneurysmal aorta. Life Sci, 2002; 71: 2195-205
76. Moskowitz DW et al: Evidence for acute renal cortical vasoconstriction after uninephrectomy. Renal Failure, 1996; 18: 833-46
77. Moskowitz DW: From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Tech. Therapeutics, 2002; 4: 519-32
78. Moskowitz DW: Is 'somatic' angiotensin I-converting enzyme a mechanosensor? Diabetes Tech Therapeutics, 2002; 4; 841-58
79. Dalbeth N, Edwards J, Fairchild S et al: The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford), in press.
80. Kapturczak MH, Wasserfall C, Brusko T et al: Heme oxygenase-1 modulates early inflammatory response: evidence from the heme oxygenase-1-deficient mice. Am J Pathol, 2004; 165: 1045-53
81. Dell'Italia LJ, Husain A: Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol, 2002; 17: 374-79
82. Miyazaki M, Takai S: Local angiotensin II-generating system in vascular tissues: The roles of chymase. Hypertens Res, 2001; 24: 189-93
83. Petrie MC, Padmanabhan N, McDonald JE et al: Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol, 2001; 37: 1056-61
84. Wei CC, Tian B, Perry G et al: Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol, 2002; 282: H2254-H2258
85. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol, 2003; 14: 1738-47
86. Mann DL, Deswal A: Angiotensin-receptor blockade in acute myocardial infarction-a matter of dose. N Engl J Med, 2003; 349: 1963-65
87. McMurray JJ, Ostergren J. Swedberg K et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-comerting enzyme inhibitors: the CHARM-added trial. Lancet, 2003; 362: 767-71
88. Ju H, Gros R, Yon X et al: Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA, 2001; 98: 7469-74
89. Nishimoto M, Takai S, Kim S et al. Significance of chymase-dependent angiotensin-II-forming pathway in the development of vascular proliferation. Circulation, 2001; 104: 1274-79
90. Uehara Y, Urata H, Ideishi M et al: Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res, 2002; 55: 87-76